Bristol Myers Sqibb News (NYSE:BMY)

03/30/20176:59AMBWBristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Pred...
Bristol-Myers Squibb Company (NYSE:BMY) and Foundation Medicine (NASDAQ:FMI) today announced a collaboration that leverages Foundation Medicine’s comprehensive genomic profiling and molecular information solutions to identify predictive biomarkers such as Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI... More...>>
03/29/201712:30AMDJNFDA Nominee Plans Recusals From Decisions on Many Drug Firms
By Thomas M. Burton The Trump administration's nominee to lead the Food and Drug Administration plans to recuse himself for a year from FDA decisions on more than 20 companies, including some drug giants. Scott Gottlieb in recent years has held positions and received millions of dollars in income as adviser, executive... More...>>
03/28/20176:59AMBWParker Institute for Cancer Immunotherapy, Bristol-Myers Squibb & the Cancer Research Institute Announce Collaboration to Acc...
Innovative collaboration model designed to accelerate next-generation precision cancer immunotherapy through network of leading research centers and top scientists Collaboration will leverage efficiencies in cancer research to rapidly implement novel Immuno-Oncology clinical studies Bristol-Myers Squibb is the first industry... More...>>
03/24/20178:31AMBWBristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer...
First Immuno-Oncology agent to receive positive CHMP opinion for the treatment of an advanced form of head and neck cancer Positive opinion based on overall survival benefit demonstrated in the Phase 3 CheckMate -141 trial Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products... More...>>
03/20/20176:59AMBWBristol-Myers Squibb & CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatme...
Builds upon initial 2014 alliance in oncology Includes up to eight additional targets in oncology and other therapeutic areas CytomX to receive $200 million upfront payment Bristol-Myers Squibb Company (NYSE:BMY) and CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody... More...>>
03/17/201711:15AMBWBristol-Myers Squibb & Pfizer Present Large Real-World Observational Analysis of the Effectiveness & Safety of Direct Oral An...
In this U.S. Medicare database analysis, Eliquis® (apixaban) was associated with significantly lower risk of stroke or systemic embolism and lower rate of major bleeding compared to warfarin Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced findings from a real-world data analysis of the... More...>>
03/10/201710:20AMBWBristol-Myers Squibb to Announce Results for First Quarter 2017 on April 27
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the first quarter of 2017 on Thursday, April 27, 2017. During a conference call at 10:30 a.m. EDT on April 27, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are... More...>>
03/09/20173:02AMDJNWhat's News: Business & Finance -- WSJ
Oil prices plunged 5.4% to $50.28 a barrel on the Nymex, the biggest drop in over a year, after U.S. data showed a record surplus. U.S. stocks slipped as the decline in oil hit energy firms. The Dow lost 69.03 points to 20855.73. Big oil firms are moving away from extravagant projects and investing in cheaper, quicker... More...>>
03/09/20173:02AMDJNBristol Appoints New R&D Chief -- WSJ
Cancer doctor on drugmaker's board is leaving executive post at Boston hospital By Jonathan D. Rockoff Bristol-Myers Squibb Co. said it would replace its research-and-development chief, naming a Massachusetts General Hospital executive to the key job as the company seeks to move past a major drug-development setback... More...>>
03/08/201712:24PMBWBristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has appointed Dr. Thomas J. Lynch, Jr., 56, executive vice president and chief scientific officer, effective March 16, 2017. He succeeds Dr. Francis Cuss, 62, who will retire from the company. Dr. Cuss will serve as an advisor to the company for the next three... More...>>
03/08/201712:04PMDJNBristol-Myers Squibb Names New R&D Chief
By Jonathan D. Rockoff Bristol-Myers Squibb Co. said it would replace its research-and-development chief, naming a Massachusetts General Hospital executive to the key job as the company seeks to move past a major drug-development setback. Thomas Lynch Jr., a Bristol board member and cancer doctor who has been overseeing... More...>>
03/08/20179:00AMBWBristol-Myers Squibb to Take Part in Barclays Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will present at Barclays Global Health Care Conference on Wednesday, March 15, 2017, in Miami. Charles Bancroft, executive vice president and chief financial officer, will answer questions about the company at 8:30 a.m. EDT. Investors and the general public are invited to listen... More...>>
03/06/20179:47AMDJNRace Tightens for Next Wave of Cancer Drugs
By Peter Loftus WILMINGTON, Del. -- In the race to develop the next wave of drugs that use the immune system to fight cancer, scientists scurry up and down escalators in an old department store here. Their biotechnology company, Incyte Corp., set up shop in a former John Wanamaker store on the outskirts of Wilmington in... More...>>
03/06/20178:30AMBWBristol-Myers Squibb & Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical & Real-World Data at the American Col...
Post-hoc Analyses from the ARISTOTLE Trial Featured in Late-Breaker and Poster Sessions Real-World Data Analyses Include Database Reviews of U.S. Medicare Patient Population Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced that eight abstracts have been accepted for presentation at the... More...>>
03/02/20174:34PMBWBristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-nine cents ($0.39) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on May 1, 2017, to stockholders of record at the close of business on April 7, 2017... More...>>
03/01/20176:20PMBWBristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology & ...
First report of data evaluating investigational selective IDO1 inhibitor alone and in combination with Opdivo Initial presentation of overall survival data from Phase 3 CheckMate -067 assessing Opdivo monotherapy or in combination with Yervoy versus Yervoy alone in patients with advanced melanoma First report of five-year... More...>>
03/01/20178:10AMBWBristol-Myers Squibb Expands Focus on Precision Medicine with Investment & Planned Collaboration with GRAIL on Blood-Based Ca...
Companies to enter a research collaboration that utilizes GRAIL’s future analytics tools to inform research, advance diagnostics and improve patient outcomes Bristol-Myers Squibb Company (NYSE: BMY) announced today its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose... More...>>
02/27/20179:30AMBWBristol-Myers Squibb to Take Part in Cowen and Company 37th Annual Global Health Care Conference
Bristol-Myers Squibb Company (NYSE: BMY) will present at the Cowen and Company 37th Annual Global Health Care Conference on Monday, March 6, 2017, in Boston. Giovanni Caforio, chief executive officer, will make a formal presentation about the company at 2:00 p.m. EST. Investors and the general public are invited to listen... More...>>
02/27/20176:59AMBWExelixis & Bristol-Myers Squibb Enter Clinical Collaboration for Late-Stage Combination Trial in First-Line Renal Cell Carcin...
Companies intend to initiate pivotal trial evaluating CABOMETYX™ (cabozantinib) with Opdivo® (nivolumab) alone or in combination with Yervoy® (ipilimumab) in first-line renal cell carcinoma Planning additional studies in bladder cancer and hepatocellular carcinoma Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb... More...>>
02/27/20176:59AMBWBristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Cente...
With over 250 investigators, the II-ON has undertaken more than 150 research projects across 20 tumor types including 12 clinical trials since its launch in 2012 Global collaboration now includes 15 leading academic institutions Bristol-Myers Squibb Company (NYSE:BMY) today announced that Columbia University Medical Center... More...>>
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:us D:20170330 18:29:40